Prestige BioPharma Limited
KSE:950210.KS
13500 (KRW) • At close September 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) KRW.
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|
| Assets: | ||||||
| Current Assets: | ||||||
| Cash & Cash Equivalents
| 125,021.951 | 268,650.508 | 458,975.123 | 45,976.24 | 9,826.473 | 3,718.397 |
| Short Term Investments
| 176,390.48 | 34,619.069 | 377.683 | 2,422.781 | 0 | 0 |
| Cash and Short Term Investments
| 301,412.431 | 303,269.577 | 459,352.806 | 48,399.021 | 9,826.473 | 3,718.397 |
| Net Receivables
| 133.212 | 0 | 649.558 | 2,427.119 | 1,951.358 | 1,364.162 |
| Inventory
| 7,146.027 | 2,156.949 | -155.88 | -2,429.647 | 0 | 0 |
| Other Current Assets
| 21,369.003 | 6,139.104 | 90.4 | 1,414.887 | 8,254.511 | 20.56 |
| Total Current Assets
| 311,475.621 | 311,565.63 | 459,936.884 | 49,811.379 | 20,032.343 | 5,103.119 |
| Non-Current Assets: | ||||||
| Property, Plant & Equipment, Net
| 310,438.169 | 38,342.182 | 6,437.462 | 4,518.716 | 1,044.39 | 890.493 |
| Goodwill
| 10,191.578 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets
| 108,719.695 | 65,312.308 | 109,022.985 | 95,010.695 | 68,267.258 | 0 |
| Goodwill and Intangible Assets
| 118,911.273 | 65,312.308 | 109,022.985 | 95,010.695 | 68,267.258 | 0 |
| Long Term Investments
| -175,615.339 | 40,090.999 | 23,780.857 | 6,912.887 | 9,281 | 6,068.22 |
| Tax Assets
| 0 | 34,619.069 | 3,559.912 | 2,422.781 | 0 | 0 |
| Other Non-Current Assets
| 176,390.48 | 9,883.041 | 1,428.321 | 1,421.628 | 4,298.192 | 29,187.916 |
| Total Non-Current Assets
| 430,124.583 | 188,247.599 | 144,229.537 | 110,286.707 | 82,890.84 | 36,146.629 |
| Total Assets
| 741,600.204 | 499,813.229 | 604,166.42 | 160,098.087 | 102,923.183 | 41,249.748 |
| Liabilities & Equity: | ||||||
| Current Liabilities: | ||||||
| Account Payables
| 462.148 | 2,623.877 | -563.075 | -231.911 | 0 | 5,340.54 |
| Short Term Debt
| 32,857.077 | 1,593.383 | 4,199.42 | 443.835 | 18,474.399 | 6,755.539 |
| Tax Payables
| 0 | 632.311 | 0 | 0 | 0 | 0 |
| Deferred Revenue
| 100,024.975 | 34,124.7 | 563.075 | 231.911 | 1,710.017 | 0 |
| Other Current Liabilities
| 1,543.852 | 3,452.173 | 9,847.059 | 8,032.981 | 13,581.594 | 0 |
| Total Current Liabilities
| 134,888.052 | 41,794.133 | 14,046.479 | 8,476.816 | 33,766.01 | 12,096.079 |
| Non-Current Liabilities: | ||||||
| Long Term Debt
| 51,516.294 | 2,655.876 | 3,571.377 | 2,434.596 | 48.118 | 38.65 |
| Deferred Revenue Non-Current
| 1,592.722 | 25,427.363 | 11,587.909 | 11,387.215 | 10,911.442 | 1,114.499 |
| Deferred Tax Liabilities Non-Current
| 7,368.339 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities
| 0.001 | 0.001 | 0.001 | 0 | 10.413 | 10.898 |
| Total Non-Current Liabilities
| 60,477.356 | 28,083.24 | 15,159.287 | 13,821.811 | 10,969.972 | 1,164.047 |
| Total Liabilities
| 195,365.408 | 69,877.373 | 29,205.765 | 22,298.627 | 44,735.982 | 13,260.125 |
| Equity: | ||||||
| Preferred Stock
| 0 | 0 | 0 | 0 | 0 | 0 |
| Common Stock
| 690,174.731 | 679,712.759 | 594,071.79 | 152,779.419 | 61,425.631 | 31,427.201 |
| Retained Earnings
| -246,151.329 | -259,601.048 | -27,954.242 | -21,890.737 | -6,568.803 | -4,919.462 |
| Accumulated Other Comprehensive Income/Loss
| 6,511.115 | 9,865.938 | 8,812.979 | 6,923.151 | 3,330.373 | 2.092 |
| Other Total Stockholders Equity
| -23.964 | -41.793 | 30.128 | -12.374 | -0 | 1,479.791 |
| Total Shareholders Equity
| 450,510.553 | 429,935.856 | 574,960.655 | 137,799.459 | 58,187.201 | 27,989.622 |
| Total Equity
| 546,234.796 | 429,935.856 | 574,960.655 | 137,799.459 | 58,187.201 | 27,989.622 |
| Total Liabilities & Shareholders Equity
| 741,600.204 | 499,813.229 | 604,166.42 | 160,098.086 | 102,923.183 | 41,249.748 |